Suppression of serum tumour necrosis factor-α by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid

Anticancer Research

Volumn 18, Issue 6 A, 1998, Pages 4409-4413

  Browne, William L ^a   Wilson, William R ^b   Baguley, Bruce C ^a   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Adenocarcinoma; Blood flow; Flavone acetic acid; Tumor necrosis factor

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CYTOKINE; PIPERIDINE DERIVATIVE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD FLOW; BLOOD VESSEL; BREAST CARCINOMA; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; FEMALE; IMMUNE SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR NECROSIS;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; REGIONAL BLOOD FLOW; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES; XANTHONES;

EID: 0032423964     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC and Denny WA: Potential antitumor agents. 61. Structure-activity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217-222, 1991.
2. Kerr DJ and Kaye SB: Flavone acetic acid - preclinical and clinical activity. Eur J Cancer Clin Oncol 25: 1271-1272, 1989.
3. Zwi LJ, Baguley BC, Gavin JB and Wilson WR: Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6: 79-85, 1994.
4. Mace KF, Hornung RL, Wiltrout RH and Young HA: Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res 50: 1742-1747, 1990.
5. Philpott M, Baguley BC and Ching L-M: Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36: 143-148, 1995.
6. Thomsen LL, Ching LM, Zhuang L, Gavin JB and Baguley BC: Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51: 77-81, 1991.
7. Baguley BC, Zhuang L and Kestell P: Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine - relation to vascular effects. Oncol Res 9: 55-60, 1997.
8. Ching LM, Joseph WR, Crosier KE and Baguley BC: Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54: 870-872, 1994.
9. Philpott M, Joseph WR, Crosier KE, Baguley BC and Ching L-M: Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 76: 1586-1591, 1997.
10. Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA and Smith GP: Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on Colon 38 tumors in mice. Eur J Cancer Clin Oncol 25: 263-269, 1989.
11. Pratesi G, Rodolfo M, Rovetta G and Parmiani G: Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer 26: 1079-1083, 1990.
12. Zwi U, Baguley BC, Gavin JB and Wilson WR: Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J Natl Cancer Inst 81: 1005-1013, 1989.
13. Mahadevan V, Malik STA, Meager A, Fiers W, Lewis GP and Hart IR: Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 50: 5537-5542, 1990.
14. Sampaio EP, Sarno EN, Galilly R, Cohn ZA and Kaplan G: Thalidomide selectively inhibits tumor necrosis factor-alpha production by stimulated human monocytes. J Exp Med 173: 699-703, 1991.
15. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA and Kaplan G: Thalidomide exerts its inhibitory action on tumour necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177: 1675-1680, 1993.
16. Fabro S, Smith RL and Williams RT: Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215: 296, 1967.